Akari Therapeutics enters merger deal with Peak Bio
06 Mar 2024
Orphan DrugImmunotherapyFast TrackPhase 3Phase 2
Preview
Source: Pharmaceutical Technology
Akari Therapeutics has signed a definitive agreement with Peak Bio to merge in an all-stock transaction, creating a diversified pipeline with assets across various development stages.
The merged entity will operate under the name Akari Therapeutics Plc.
Shareholders of both companies will hold approximately 50% equity in the new entity.
The combined pipeline will have an antibody-drug-conjugate (ADC) toolkit with payload and linker technologies.
See Also:PTC TherapeuticsPTC Therapeutics files patent for pharmaceutical composition for treating various diseases
Preview
Source: Pharmaceutical Technology
Sorrento Therapeutics files patent for stable oral liquid pharmaceutical composition of celecoxib for pain relief
Preview
Source: Pharmaceutical Technology
The combined business will merge chemotherapy with immunotherapy strategies for the development of new solutions for cancer.
Akari’s lead product, nomacopan, is a bispecific recombinant inhibitor of complement C5 and leukotriene B4.
This product is currently in a Phase III clinical trial for paediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.
The FDA previously granted orphan drug, fast track and rare paediatric disease designations to nomacopan for this patient population.
It also received orphan drug designation from the European Commission for the treatment of hematopoietic stem cell transplantation.
Another asset of Akari, PASylated-nomacopan, a long-acting type of nomacopan, is nearing the end of pre-clinical development, targeting geographic atrophy with the promise of extending the dosing interval and reducing the risk of choroidal neovascularisation.
Peak Bio will also contribute its PHP-303, a Phase II-ready programme for treating alpha-1 antitrypsin deficiencyalpha-1 antitrypsin deficiency, licensed from Bayer Healthcare.
The transaction will be completed in the second quarter of 2024, pending shareholder approval and other customary closing conditions. Post-merger, the company plans to prioritise its programmes, establish updated timelines and explore near-term value-creation opportunities.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.